According to previous pre-clinical evidence, prolonged Nrf2/HO-1 downregulation initiates the development of several neurological disorders, including amyotrophic lateral sclerosis (ALS) [23], Alzheimer’s disease (AD) [24], Parkinson’s disease (PD) [25], and Huntington’s disease (HD) [26]. This evidence concerns the gene NFE2L2 and Parkinson disease.